PDS Biotechnology Corporation
Research PDS Biotechnology Corporation (PDSB) on Bullrun: market cap USD 12.41M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPDSB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 12.41M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 7.35M
- Free cash flow-USD 23.09M
Valuation Snapshot
latest market cap is USD 12.41M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 34.50M | -USD 27.75M | n/a | -0.74 | USD 26.71M | USD 16.93M | USD 9.25M |
| FY2024 | USD 0 | -USD 37.61M | -USD 35.06M | n/a | -1.03 | USD 41.69M | USD 21.83M | USD 19.00M |
| FY2023 | n/a | -USD 42.94M | -USD 33.64M | n/a | -1.39 | USD 56.56M | USD 23.85M | USD 26.13M |
| FY2022 | n/a | -USD 40.85M | n/a | n/a | -1.43 | USD 73.82M | USD 394.66K | USD 44.00M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 12.41M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 42.26M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 61.92M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 154.61M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 381.32M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 230.43M | n/a | n/a | n/a |
About PDS Biotechnology Corporation
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PDS Biotechnology Corporation's market cap?
PDS Biotechnology Corporation's market capitalization is USD 12.41M.
What does PDS Biotechnology Corporation do?
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.